Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...
Background Complex breast surgery, including immediate breast reconstruction and oncoplastic procedures, is increasingly performed to optimise oncologic and aesthetic outcomes. Postoperative wound ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
A year after an FDA rejection, Johnson & Johnson has won approval for a more convenient version of its lung cancer drug Rybrevant to better challenge AstraZeneca’s Tagrisso. Rybrevant Faspro, a ...
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET inhibitor, Rybrevant (amivantamab). This version, which will be marketed ...
Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...
Mosunetuzumab's subcutaneous formulation offers a 1-minute injection, improving convenience over the previous intravenous infusion for relapsed or refractory follicular lymphoma. The phase 1/2 GO29781 ...
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...
Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...
Mounjaro’s typical starting dosage is 2.5 milligrams (mg) once per week for 4 weeks, after which your doctor may increase the dose to 5 mg per week if needed to manage blood sugar levels. The ...
The simple interest formula is Interest = P * R * T. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take certain actions on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results